Literature DB >> 12716261

Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex.

Stephen M Stahl1.   

Abstract

ISSUE: Selective norepinephrine reuptake inhibitors exploit the fact that dopamine transporters are absent in prefrontal cortex, so dopamine has to hitchhike a ride on the norepinephrine transporter in order to be inactivated. Thus, blocking norepinephrine transporters leads to an increase in both dopamine and norepinephrine levels in prefrontal cortex as well as improvement in cognition in attention-deficit/hyperactivity disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716261

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.

Authors:  D Weintraub; S Mavandadi; E Mamikonyan; A D Siderowf; J E Duda; H I Hurtig; A Colcher; S S Horn; S Nazem; T R Ten Have; M B Stern
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

Review 2.  Biomarkers in the diagnosis of ADHD--promising directions.

Authors:  Stephen V Faraone; Cristian Bonvicini; Catia Scassellati
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 3.  Candidate gene studies of ADHD: a meta-analytic review.

Authors:  Ian R Gizer; Courtney Ficks; Irwin D Waldman
Journal:  Hum Genet       Date:  2009-06-09       Impact factor: 4.132

Review 4.  Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.

Authors:  Nicholas T Bello
Journal:  Patient Prefer Adherence       Date:  2015-06-30       Impact factor: 2.711

Review 5.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.